Press coverage about Smith & Nephew SNATS (NYSE:SNN) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Smith & Nephew SNATS earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 47.0158549719567 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Several research analysts have commented on SNN shares. Zacks Investment Research upgraded shares of Smith & Nephew SNATS from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 12th. BidaskClub cut shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Six investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Smith & Nephew SNATS presently has a consensus rating of “Hold” and an average price target of $38.00.

Smith & Nephew SNATS (NYSE SNN) traded down 1.93% on Thursday, reaching $34.99. 283,209 shares of the company’s stock traded hands. The firm’s 50-day moving average is $34.91 and its 200 day moving average is $32.95. The stock has a market capitalization of $15.32 billion, a PE ratio of 17.82 and a beta of 0.76. Smith & Nephew SNATS has a 52-week low of $26.97 and a 52-week high of $35.85.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/10/smith-nephew-snats-snn-given-news-impact-rating-of-0-22.html.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Insider Buying and Selling by Quarter for Smith & Nephew SNATS (NYSE:SNN)

Receive News & Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.